Know Cancer

or
forgot password

A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL


N/A
18 Years
N/A
Open (Enrolling)
Both
Lymphoma, B-Cell

Thank you

Trial Information

A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL


Inclusion Criteria:



- Histologically confirmed CD20+ diffuse large B-cell lymphoma or follicular lymphoma

- Treatment with MabThera/Rituxan as per locally approved China package insert

- Documented patient with medical records

Exclusion Criteria:

- Previous treatment for diffuse large B-cell lymphoma or follicular lymphoma

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Safety: Incidence of adverse events

Outcome Time Frame:

4.5 years

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

China: Ministry of Health

Study ID:

ML25435

NCT ID:

NCT01340443

Start Date:

January 2011

Completion Date:

April 2016

Related Keywords:

  • Lymphoma, B-Cell
  • Lymphoma
  • Lymphoma, Follicular
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Name

Location